8-K: Genprex Secures $2.7M, Addresses Nasdaq Compliance

Genprex, Inc. announced a registered direct offering raising $2.7 million, with potential for an additional $5.4 million from warrant exercises, as it works to regain Nasdaq listing compliance.

Summary

• Genprex, Inc. entered into definitive agreements on October 23, 2025, for a registered direct offering and concurrent private placement.
• The company will sell 243,622 shares of common stock at a purchase price of $11.21 per share.
• In a concurrent private placement, unregistered short-term warrants to purchase up to 487,244 shares of common stock will be issued, with an exercise price of $11.00 per share.
• The offering is expected to close on or about October 24, 2025.
• Gross proceeds from the direct offering are expected to be approximately $2.7 million, with potential additional gross proceeds of $5.4 million if all private warrants are fully exercised for cash, totaling $8.1 million in potential gross proceeds.
• Net proceeds from the offering, after deducting placement agent fees and other offering expenses, are expected to be approximately $2.3 million, intended for working capital and general corporate purposes.
• H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a 7.0% cash fee and a 1.0% management fee of gross proceeds, plus expense reimbursements.
• Placement Agent Warrants to purchase 14,617 shares (6.0% of shares sold) will be issued, with an exercise price of $14.0125 per share and an expiration date of the earlier of 24 months from resale registration effectiveness or October 23, 2030.
• Genprex implemented a one-for-fifty (1:50) reverse stock split on October 21, 2025, to regain compliance with Nasdaq's $1.00 Minimum Bid Price requirement.
• The Nasdaq Hearings Panel granted an exception for compliance with the Minimum Bid Price and Minimum Stockholders Equity requirements through October 31, 2025.

Sentiment

Score: 3

Explanation: While the capital raise provides immediate funding, the necessity of a reverse stock split and the ongoing Nasdaq listing compliance issues (with a short-term exception and no guarantee of further extensions) point to significant operational and financial challenges. The dilution from the offering and warrants, coupled with the uncertainty of future financing for the equity requirement, creates a negative outlook despite the immediate cash infusion.

Positives

• Secured $2.7 million in gross proceeds immediately, with potential for an additional $5.4 million from warrant exercises, providing capital for working capital and general corporate purposes.
• The offering is priced at-the-market under Nasdaq rules, indicating market acceptance of the share price.
• The company has a clear plan to address Nasdaq listing deficiencies, including a recently completed reverse stock split and ongoing efforts to raise capital.
• The company's oncology programs (NSCLC and SCLC) have received Fast Track Designation from the FDA, and its SCLC program has received FDA Orphan Drug Designation, highlighting regulatory recognition of its therapies.

Negatives

• The company is currently not in compliance with Nasdaq's $1.00 Minimum Bid Price and Minimum Stockholders Equity requirements, necessitating an exception from the Nasdaq Hearings Panel.
• The Nasdaq compliance exception is only granted through October 31, 2025, with no guarantee of further extensions.
• Additional capital raising transactions are believed to be needed to regain compliance with the Minimum Stockholders Equity Requirement, and there is no assurance such financing will be available on acceptable terms or at all.
• The issuance of new shares and warrants will dilute existing shareholders.
• Significant fees and expenses are associated with the offering, including 8.0% of gross proceeds to the placement agent, plus additional reimbursements and warrants.

Risks

• Inability to regain and maintain compliance with Nasdaq's continued listing requirements, potentially leading to delisting.
• Uncertainty regarding the availability of additional financing on acceptable terms to meet the Minimum Stockholders Equity Requirement.
• No assurance that the short-term warrants will be exercised for cash, limiting potential additional proceeds.
• Risks associated with the company's financial position and market conditions, as detailed in periodic reports.
• The company does not intend to revise or update forward-looking statements, except as required by law, which could lead to outdated information.
• Potential negative impact on the market price of common stock from past or future open market or derivative transactions by purchasers, including Short Sales.
• The Nasdaq Panel reserves the right to reconsider the exception terms based on any event, condition, or circumstance.

Future Outlook

The company expects to use the net proceeds from the offering for working capital and general corporate purposes. It intends to file a registration statement on Form S-1 for the resale of Private Warrant Shares within 30 calendar days and aims for it to become effective within 60 to 90 calendar days. The company believes it will need to engage in additional capital raising transactions to regain compliance with Nasdaq's Minimum Stockholders Equity Requirement, though there is no guarantee such financing will be available. It plans to provide prompt notification to the Nasdaq Hearings Panel of any significant events and may request a further extension beyond October 31, 2025, for compliance.

Management Comments

• We intend to use the net proceeds from the offering for working capital and general corporate purposes.
• We believe we will need to engage in additional capital raising transactions to regain compliance with the Minimum Stockholders Equity Requirement, and there is no guarantee that such financing will be available on terms acceptable to the Company, or at all.
• We fully intend to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception.

Industry Context

This financing event is typical for clinical-stage biotechnology or gene therapy companies like Genprex, which often require significant capital to fund research, development, and clinical trials. The need for a reverse stock split and the ongoing Nasdaq compliance issues suggest the company is facing financial and market challenges, which is not uncommon for companies in this high-risk, high-reward industry. The Fast Track and Orphan Drug Designations indicate potential for their therapies, but also highlight the long development timelines and regulatory hurdles inherent in the sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Experience immediate dilution from the issuance of new shares and potential further dilution from warrant exercises. The reverse stock split reduces the number of shares outstanding but does not change the underlying value, though it can be perceived negatively. Nasdaq compliance issues create uncertainty regarding continued listing.
• Investors (Purchasers in Offering): Acquire shares and warrants at a specified price, with potential for future gains if the stock price increases and warrants are exercised. They are subject to beneficial ownership limitations.
• Placement Agent (H.C. Wainwright & Co.): Receives significant fees and warrants for facilitating the offering, along with a right of first refusal for future capital raises.

Next Steps

• Closing of the offering on or about October 24, 2025.
• Company to file a registration statement on Form S-1 for the resale of Private Warrant Shares within 30 calendar days of the Purchase Agreement date.
• Company to use commercially reasonable efforts to cause the S-1 registration statement to become effective within 60 calendar days (or 90 days if full SEC review).
• Company to maintain listing or quotation of Common Stock on Nasdaq and apply to list all Shares and Warrant Shares.
• Company to provide prompt notification to the Nasdaq Hearings Panel of any significant events.
• Company may request a further extension beyond October 31, 2025, to regain Nasdaq compliance.
• Company believes it will need to engage in additional capital raising transactions to regain compliance with the Minimum Stockholders Equity Requirement.

Key Dates

Recommendation

The company is undertaking a capital raise at a time when it is struggling with Nasdaq compliance, having just completed a 1:50 reverse stock split to meet minimum bid price requirements. The current Nasdaq exception is short-term, and the company explicitly states it needs additional capital to meet the minimum stockholders' equity requirement, with no guarantee of securing it. This indicates significant financial distress and ongoing uncertainty about its ability to maintain its listing. While the capital raise provides a temporary cash infusion, the underlying issues suggest a high-risk investment with potential for further dilution and delisting, making it a 'sell' for a seasoned investor.

Keywords

Genprex, GNPX, Registered Direct Offering, Private Placement, Warrants, Nasdaq Compliance, Reverse Stock Split, Capital Raise, Gene Therapy, Oncology, Diabetes, SEC Filing, Equity Financing, H.C. Wainwright & Co.